| Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. | |
| | |
MedLine Citation:
|
PMID: 20575003 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The ability to deliver nucleic acids (e.g., plasmid DNA, antisense oligonucleotides, siRNA) offers the potential to develop potent vaccines and novel therapeutics. However, nucleic acid-based therapeutics are still in their early stages as a new category of biologics. The efficacy of nucleic acids requires that these molecules be delivered to the interior of the target cell, which greatly complicates delivery strategies and compromises efficiency. Due to the safety concerns of viral vectors, synthetic vectors such as liposomes and polymers are preferred for the delivery of nucleic acid-based therapeutics. Yet, delivery efficiencies of synthetic vectors in the clinic are still too low to obtain therapeutic levels of gene expression. In this review, we focus on some key issues in the field of nucleic acid delivery such as PEGylation, encapsulation and targeted delivery and provide some perspectives for consideration in the development of improved synthetic vectors. |
| | |
Authors:
|
Long Xu; Thomas Anchordoquy |
Related Documents
:
|
16851443 - Photophysical and (photo)electrochemical properties of a coumarin dye. 392813 - A biological study on hot-water extract from delipidated mycobacterium bovis strain bcg. 15780653 - Hydrophobic substrate utilisation by the yeast yarrowia lipolytica, and its potential a... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Journal of pharmaceutical sciences Volume: 100 ISSN: 1520-6017 ISO Abbreviation: J Pharm Sci Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-16 Completed Date: 2011-03-31 Revised Date: 2011-09-22 |
Medline Journal Info:
|
Nlm Unique ID: 2985195R Medline TA: J Pharm Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 38-52 Citation Subset: IM |
Copyright Information:
|
2010 Wiley-Liss, Inc. and the American Pharmacists Association |
Affiliation:
|
Department of Pharmaceutical Sciences, University of Colorado, 12700 East Nineteenth Avenue, Aurora, Colorado 80045, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Biological Therapy / trends* Chemistry, Pharmaceutical Drug Delivery Systems / trends* Humans Nucleic Acids / administration & dosage*, therapeutic use* Oligonucleotides / administration & dosage, therapeutic use Oligonucleotides, Antisense / administration & dosage, therapeutic use Plasmids / administration & dosage, therapeutic use RNA, Small Interfering / administration & dosage, therapeutic use Vaccines, DNA / administration & dosage, therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
EB005476-01A2/EB/NIBIB NIH HHS; R01 EB005476-01A2/EB/NIBIB NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Nucleic Acids; 0/Oligonucleotides; 0/Oligonucleotides, Antisense; 0/RNA, Small Interfering; 0/Vaccines, DNA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Investigation of solution and vapor phase mediated phase transformation in thiamine hydrochloride.
Next Document: Comminution of carbohydrate and protein microparticles on firing in a ballistic powder injector.